



Supplementary Figure 11


Baseline - OS




Baseline - PFS



Cycle 3 - OS



Cycle 3 - PFS



**Supplementary Figure 11. Multivariable analysis of OS and PFS using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab.** CMC was determined using a bespoke targeted approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown in a multivariable analysis including cohort, PD-L1 expression, and tumor mutation burden (TMB).